These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18221063)

  • 1. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
    Kageyama Y; Hyochi N; Kihara K; Sugiyama H
    Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
    Sharifi N
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
    Dehm SM; Tindall DJ
    J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations during progression of prostate cancer to androgen independence.
    Saraon P; Jarvi K; Diamandis EP
    Clin Chem; 2011 Oct; 57(10):1366-75. PubMed ID: 21956922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer.
    Edwards J; Krishna NS; Mukherjee R; Watters AD; Underwood MA; Bartlett JM
    BJU Int; 2001 Oct; 88(6):633-7. PubMed ID: 11678763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    Taplin ME; Balk SP
    J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostate cancer and apoptosis].
    Mayora A; Arvelo F
    Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.